TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29183701

Group type: EXPERIMENTAL
Intervention: Snack positioned far (70 cm)
Number of subjects: 405

Group type: COMPARATOR
Intervention: Snack positioned near (20 cm)
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Snack positioned far (70 cm) after removing non-adherers
Number of subjects: 405

Group type: COMPARATOR
Intervention: Snack positioned near (20 cm) after removing non-adherers
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Snack positioned far (70 cm) in Study 2 after removing non-adherers
Number of subjects: 405

Group type: COMPARATOR
Intervention: Snack positioned near (20 cm) in Study 2 after removing non-adherers
Number of subjects: 405
Study: 27372560

Group type: EXPERIMENTAL
Intervention: Percutaneous mitral valve repair (catheter-based clip implantation)
Number of subjects: 46
Study: 24404797

Group type: EXPERIMENTAL
Intervention: Oral corticosteroids (OC)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 70
Study: 22951317

Group type: EXPERIMENTAL
Intervention: Citicoline 1000mg (test preparation)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Citicoline 1000mg (reference control release tablet)
Number of subjects: 12
Study: 21110257

Group type: EXPERIMENTAL
Intervention: Transition Assistance Program (TAP)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 122
Study: 18039433

Group type: EXPERIMENTAL
Intervention: Oxycodone (prolonged-release form)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 0
Study: 16462818

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 120 mg Orlistat three times a day
Number of subjects: 28

Group type: COMPARATOR
Intervention: Diet (energy- and fat-restricted)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Diet continuation for 1 year
Number of subjects: 28
Study: 12478093

Group type: EXPERIMENTAL
Intervention: Finasteride (12 patients, treated for a minimum of 6 weeks before surgery)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (12 patients, not treated with finasteride)
Number of subjects: 24
Study: 10735889

Group type: EXPERIMENTAL
Intervention: Adjuvant endocrine treatment (n = 250)
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (n = 112)
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Overall patient population
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Adjuvant endocrine treatment
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Nodal status, estrogen receptor (ER) status, tumor size
Number of subjects: 362
Study: 8774551

Group type: EXPERIMENTAL
Intervention: 6 methylprednisolone (6MP) i.v. for 3 days at 5 mg/kg/d and for an additional 3 days at 2.5 mg/kg/d followed by po prednisone (1 mg/kg/d)
Number of subjects: 22

Group type: COMPARATOR
Intervention: po prednisone (1 mg/kg/d)
Number of subjects: 22
Study: 1635824

Group type: EXPERIMENTAL
Intervention: Inspiratory flow-resistive load training (75 cm H2O.L-1.s in week 1 and 90 cm H2O.L-1.s in week 2)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Inspiratory flow-resistive load training
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 22
Study: 6708393

Group type: EXPERIMENTAL
Intervention: Cardiac glycosides only (group II)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Digitalis and diuretics (group III)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Digitalis and K+-saving diuretics (group IV)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Digitalis and K+-losing diuretics (group V)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Digitalis and furosemide (chronic hypokalemia, group VI)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control (group I)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (control group)
Number of subjects: 143
Study: 31490414

Group type: EXPERIMENTAL
Intervention: UEScope videolaryngoscope
Number of subjects: 0

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 0
Study: 30094725

Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 50
Study: 26228276

Group type: EXPERIMENTAL
Intervention: PMEA-coated circuits
Number of subjects: 14

Group type: COMPARATOR
Intervention: Heparin-coated circuits
Number of subjects: 14
Study: 25012934

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) 2 mg every 4 weeks (2q4)
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) 2 mg every 8 weeks after 5 initial monthly doses (2q8)
Number of subjects: 872

Group type: COMPARATOR
Intervention: Macular laser photocoagulation
Number of subjects: 872
Study: 22528165

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg (Group AA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Atorvastatin on the day of surgery and for seven days post surgery (Group PA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo at all times (Group PP)
Number of subjects: 60
Study: 19882194

Group type: EXPERIMENTAL
Intervention: Harmonic scalpel (HS)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Traditional method (TM)
Number of subjects: 140
Study: 18482525

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (intravenous insulin with target glycemia levels of 80-110 mg/dl)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional insulin therapy (subcutaneous insulin only when glycemia was 160 mg/dl)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional insulin therapy
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test after 4 weeks
Number of subjects: 28
Study: 15683372

Group type: EXPERIMENTAL
Intervention: Mifepristone (200 mg) followed by misoprostol (0.8 mg)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Mifepristone (200 mg)
Number of subjects: 34
Study: 12789384

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg initially, increased to 100 mg or decreased to 25 mg depending on efficacy and tolerance)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 133
Study: 10534249

Group type: EXPERIMENTAL
Intervention: Bilateral thalamic stimulation
Number of subjects: 9
Study: 8706436

Group type: EXPERIMENTAL
Intervention: TCu380A
Number of subjects: 874

Group type: COMPARATOR
Intervention: Cu-Fix
Number of subjects: 874
Study: 1810359

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100 mg for 1 week, then 300 mg)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Mianserin (60 mg for 1 week, then 180 mg)
Number of subjects: 59
Study: 3890918

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate ointment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ointment base (control)
Number of subjects: 0
Study: 30799538

Group type: EXPERIMENTAL
Intervention: Robotic surgery
Number of subjects: 82

Group type: COMPARATOR
Intervention: Laparoscopic surgery
Number of subjects: 82
Study: 29426288

Group type: EXPERIMENTAL
Intervention: Care management including continuous contact between care manager and patient, a structured management plan, and behavioral activation, around 6-7 contacts over 12 weeks.
Number of subjects: 192
Study: 26807956

Group type: EXPERIMENTAL
Intervention: Animal-assisted activities (AAA) with a dog, 30-min sessions twice weekly for 12 weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group with treatment as usual
Number of subjects: 58
Study: 25108482

Group type: EXPERIMENTAL
Intervention: Learning to Cope with Triggers (LCT)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Avoidance
Number of subjects: 127

Group type: COMPARATOR
Intervention: Avoidance combined with cognitive behavior therapy (Avoid + CBT)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Waiting-list (Waitlist)
Number of subjects: 127
Study: 21960369

Group type: EXPERIMENTAL
Intervention: Vitamin E-bonded dialyzer (PSVE)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Polyethersulfone membrane (polysulfone)
Number of subjects: 16
Study: 19838130

Group type: EXPERIMENTAL
Intervention: vicriviroc (5, 10, or 15 mg/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28
Study: 23021156

Group type: EXPERIMENTAL
Intervention: P3P intervention
Number of subjects: 448

Group type: COMPARATOR
Intervention: Control group (standard education plus links to reputable websites)
Number of subjects: 448
Study: 16284465

Group type: EXPERIMENTAL
Intervention: Dextrin sulphate (DS) gel twice daily
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo gel twice daily
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Dextrin sulphate (DS) gel pre-sex
Number of subjects: 109

Group type: COMPARATOR
Intervention: Observation only arm
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Dextrin sulphate (DS) gel
Number of subjects: 109
Study: 12365857

Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg orally twice daily (n=19)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg orally thrice daily (n=20)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo (n=20)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Pentoxifylline and Cilostazol (both)
Number of subjects: 59
Study: 9798811

Group type: EXPERIMENTAL
Intervention: Consensus-based local asthma guidelines using a modified Delphi approach
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Local guidelines
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Patient education and inhaled steroids usage
Number of subjects: 42
Study: 7806712

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for depression over 12 weeks
Number of subjects: 115
Study: 2791812

Group type: EXPERIMENTAL
Intervention: Intravenous cisapride (8.0 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral cisapride (10.0 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral cisapride (5.0 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous cisapride followed by intravenous atropine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisapride followed by atropine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atropine followed by cisapride
Number of subjects: 0
Study: 1130311

Group type: EXPERIMENTAL
Intervention: Vitamin B6 supplementation (0.8, 2.0, or 20.0 mg of pyridoxine hydrochloride)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Vitamin B6-deficient diet
Number of subjects: 24
Study: 29114999

Group type: EXPERIMENTAL
Intervention: Site assessment
Number of subjects: 89

Group type: COMPARATOR
Intervention: Central assessment
Number of subjects: 89

Group type: COMPARATOR
Intervention: Central review
Number of subjects: 89
Study: 28376149

Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin therapy (conjugated equine estrogen 0.625 mg plus medroxyprogesterone acetate 2.5 mg)
Number of subjects: 907

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 907
Study: 25355722

Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (T-DM1)
Number of subjects: 991

Group type: COMPARATOR
Intervention: Lapatinib plus capecitabine (XL)
Number of subjects: 991
Study: 22827235

Group type: EXPERIMENTAL
Intervention: Positive health priming intervention
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study: 21399467

Group type: EXPERIMENTAL
Intervention: Unreamed Femoral Nail (UFN; Synthes, Bettlach, Switzerland) inserted at the trochanteric fossa
Number of subjects: 17

Group type: COMPARATOR
Intervention: Long Proximal Femoral Nail (PFN; Synthes) inserted at the tip of the greater trochanter
Number of subjects: 17
Study: 18598819

Group type: EXPERIMENTAL
Intervention: Wavefront-guided (WFG) LASIK
Number of subjects: 0
Study: 17174179

Group type: EXPERIMENTAL
Intervention: Low-dose paclitaxel (1.28 microg/mm2)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: High-dose paclitaxel (3.10 microg/mm2)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 14559762

Group type: EXPERIMENTAL
Intervention: I1 - Standard logistic regression ignoring clustering
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: I4 - Random-effects logistic regression
Number of subjects: 0

Group type: COMPARATOR
Intervention: C1 - Unweighted regression of practice log odds
Number of subjects: 0

Group type: COMPARATOR
Intervention: C2 - Regression of log odds weighted by their inverse variance
Number of subjects: 0

Group type: COMPARATOR
Intervention: C3 - Random-effects meta-regression of log odds with practice as a random effect
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: I2 - Robust SE
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: I3 - Generalized estimating equations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: I5 - Bayesian random-effects logistic regression
Number of subjects: 0
Study: 10691585

Group type: EXPERIMENTAL
Intervention: Fexofenadine (60 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Diphenhydramine (50 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Alcohol (approximately 0.1% blood alcohol concentration)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fexofenadine
Number of subjects: 40
Study: 8643884

Group type: EXPERIMENTAL
Intervention: Randomized treatment (734 patients, 35% of total)
Number of subjects: 2084

Group type: COMPARATOR
Intervention: Non-randomized treatment (1350 patients, 65% of total)
Number of subjects: 2084
Study: 1315590

Group type: EXPERIMENTAL
Intervention: Embolization and chemoembolization using microencapsulated Mitomycin
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 32
Study: 3908262

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg mane
Number of subjects: 518

Group type: COMPARATOR
Intervention: Ranitidine 150 mg b.i.d.
Number of subjects: 518
Study: 29522830

Group type: COMPARATOR
Intervention: Facilitator-led learning
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Self-learning without supervision
Number of subjects: 240
Study: 27177587

Group type: EXPERIMENTAL
Intervention: Speckle tracking echocardiography (STE)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Conventional echocardiography (LVEF)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional echocardiography (SOFA score)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Conventional echocardiography (mean arterial pressure)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Conventional echocardiography (heart rate)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Conventional echocardiography (cardiac output)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Conventional echocardiography (systemic vascular resistance)
Number of subjects: 33
Study: 22767005

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (1 L the night before and 1 L on the day of the exam) with bisacodyl 10 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Mannitol (1 L of a 10% mannitol solution on the day of the exam) with bisacodyl 20 mg
Number of subjects: 100
Study: 20666948

Group type: EXPERIMENTAL
Intervention: Estrogen + progestin therapy (HT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 32
Study: 18363588

Group type: EXPERIMENTAL
Intervention: Strategy 1 of ART delivery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Strategy 2 of ART delivery
Number of subjects: 0
Study: 16181878

Group type: COMPARATOR
Intervention: Low dose AF0144 (1.8 g/kg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: High dose AF0144 (2.7 g/kg)
Number of subjects: 36
Study: 12108859

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 48
Study: 10438376

Group type: EXPERIMENTAL
Intervention: ALVAC‐CMV(gB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: ALVAC‐RG
Number of subjects: 20
Study: 7774741

Group type: EXPERIMENTAL
Intervention: Oxytocin 10 units
Number of subjects: 2040

Group type: COMPARATOR
Intervention: Syntometrine 1 ml (oxytocin 5 units + ergometrine 0.5 mg)
Number of subjects: 2040
Study: 2191071

Group type: EXPERIMENTAL
Intervention: Nopharmacological treatment group
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 91
Study: 377620

Group type: EXPERIMENTAL
Intervention: Pretransplant blood transfusions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deliberate transfusion pretreatment
Number of subjects: 0
Study: 31066315

Group type: EXPERIMENTAL
Intervention: Traditional mirror therapy (4 weeks)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Teletreatment (6 weeks)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Self-delivered mirror therapy (6 weeks)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Teletreatment usage
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Teletreatment user acceptance
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Barriers for implementation of teletreatment
Number of subjects: 51
Study: 27941333

Group type: EXPERIMENTAL
Intervention: Hepatic portal reocclusion
Number of subjects: 200

Group type: COMPARATOR
Intervention: Traditional procedure (Control)
Number of subjects: 200
Study: 26285020

Group type: EXPERIMENTAL
Intervention: Caffeine-containing supplement (CAF)
Number of subjects: 12
Study: 24343092

Group type: EXPERIMENTAL
Intervention: HIV(+)ARV(−)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: HIV(+)ARV(+)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: ARV therapy longer than 2 years
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: HIV infection
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: HIV-infected lipodystrophic patients
Number of subjects: 75

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 75
Study: 19615730

Group type: EXPERIMENTAL
Intervention: Guidelines-based optimal asthma management over 46 weeks
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Guidelines-based optimal asthma management
Number of subjects: 546
Study: 17240224

Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg orally, 4 x daily for 3 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Acetaminophen (1000 mg orally, 4 x daily for 3 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 15878195

Group type: EXPERIMENTAL
Intervention: Electron beam irradiation at 25, 100, and 200 kGy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Non-irradiated specimens
Number of subjects: 200
Study: 12477059

Group type: EXPERIMENTAL
Intervention: Juvenile idiopathic arthritis (JIA) patients
Number of subjects: 17

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 17
Study: 9402612

Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 7957450

Group type: EXPERIMENTAL
Intervention: Single oral dose of theophylline
Number of subjects: 2
Study: 3303983

Group type: EXPERIMENTAL
Intervention: Steam inhalation (two 20-minute sessions of inhaling saturated, hot air at 42-44 degrees C)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo treatment (control group)
Number of subjects: 62
Study: 31325396

Group type: EXPERIMENTAL
Intervention: Urban area students
Number of subjects: 5620

Group type: EXPERIMENTAL
Intervention: Rural area students
Number of subjects: 5620

Group type: EXPERIMENTAL
Intervention: Rural girls
Number of subjects: 5620
Study: 29936590

Group type: EXPERIMENTAL
Intervention: Epinephrine (0.2-0.4 μg/kg/min)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dopamine (10-20 μg/kg/min)
Number of subjects: 40
Study: 26322438

Group type: EXPERIMENTAL
Intervention: SOC training (6 sessions, 16.5 hours over 9 months)
Number of subjects: 70
Study: 25196061

Group type: EXPERIMENTAL
Intervention: 90 μg PEG‐IFNα‐2a weekly
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 135 μg PEG‐IFNα‐2a weekly
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: PEG‐IFNα‐2a treatment with HCV RNA negativation at 4 weeks
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: PEG‐IFNα‐2a treatment with HCV RNA positivity at 24 weeks
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Treatment discontinuation due to adverse events
Number of subjects: 56
Study: 22843377

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (ICT)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Primary alternating CRT or concurrent CRT (non-ICT)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Definitive chemoradiotherapy (CRT)
Number of subjects: 97
Study: 20016011

Group type: EXPERIMENTAL
Intervention: Iron-fortified milk (FM); Daily portion contained 5.28 mg Fe (ferrous gluconate) and 48 mg sodium ascorbate
Number of subjects: 567

Group type: COMPARATOR
Intervention: Non-fortified milk (NFM); Control group
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Iron-fortified milk (FM)
Number of subjects: 567
Study: 17573492

Group type: EXPERIMENTAL
Intervention: Good compliance to CPAP treatment (n = 20)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Poor compliance to CPAP treatment (n = 19)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Refusal of CPAP treatment (n = 14)
Number of subjects: 53
Study: 16213352

Group type: EXPERIMENTAL
Intervention: Low-dose histidine-tryptophan-ketoglutarate (HTK) solution
Number of subjects: 21

Group type: COMPARATOR
Intervention: Cold crystalloid cardioplegia
Number of subjects: 21
Study: 12734238

Group type: EXPERIMENTAL
Intervention: BACTEC 13A
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: BACTEC MYCO/F LYTIC
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: BacT/ALERT MB
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: ISOLATOR 10
Number of subjects: 600
Study: 9557112

Group type: EXPERIMENTAL
Intervention: Greater saphenous vein segments from women with varicose veins
Number of subjects: 8

Group type: COMPARATOR
Intervention: Greater saphenous vein segments from women undergoing femoro‐popliteal venous bypass (control group)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Immunohistochemical analysis for oestrogen and progesterone receptors
Number of subjects: 8
Study: 8238223

Group type: EXPERIMENTAL
Intervention: Lens Opacities Classification System II
Number of subjects: 555

Group type: COMPARATOR
Intervention: Lensmeter 701
Number of subjects: 555